A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants

NCT05630287 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: [14C]-Selpercatinib
DRUG: Selpercatinib
DRUG: [14C]-Selpercatinib

Sponsor

Eli Lilly and Company

Collaborators

[object Object]